Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD1003 in ALS
NCT03114215Phase 2Completed
- Sponsor
- MedDay Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing MD1003 Arm with Placebo Arm (2 arms). Primary endpoints: Recording of adverse events at 6 months and Laboratory testing (haematology and biochemistry panel) at 6 months. Started Jun 2016; status: completed.
02
Drugs
biotin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03114215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114215.